Business Context and Reporting Period
This Form 8-K Current Report was filed by Envoy Medical, Inc. on August 24, 2026. The filing discloses the appointment of a new principal officer and the execution of an associated employment agreement.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation terms.
- Base Salary: $315,000 per year for the new Chief Accounting Officer.
- Target Bonus: 15% of base salary contingent on performance goals.
- Equity Award: 250,000 stock options with an exercise price of $0.746 per share.
- Severance: Six months of compensation under specific termination conditions.
Material Changes
On August 24, 2026, the Company appointed Robert Potashnick as Chief Accounting Officer and Vice President of Finance. Mr. Potashnick transitions from a contractor role as Interim-Chief Financial Officer to a permanent executive position. He will serve as the Company's principal financial officer and principal accounting officer.
Outlook, Risks, and Management Commentary
The filing contains no forward-looking guidance, risk factors, or management commentary regarding business operations or market conditions. The document confirms that Mr. Potashnick has no undisclosed family relationships with the Board or other officers and is not a party to any undisclosed arrangements regarding his selection.
Investor Verification Checklist
- Verify the impact of the new executive appointment on the Company's financial reporting and internal controls.
- Review the specific performance goals required to trigger the 15% target bonus.
- Confirm the dilution impact of the 250,000 stock options granted at $0.746 per share.
- Assess the Company's cash burn rate relative to the new fixed salary obligation of $315,000 annually.